Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

被引：6
作者：
Fauziya [1 ]
Gupta, Akash [1 ]
Nadaf, Arif [1 ]
Ahmad, Shadaan [1 ]
Hasan, Nazeer [1 ]
Imran, Mohammad [1 ]
Sahebkar, Amirhossein [2 ]
Jain, Gaurav Kumar [3 ]
Kesharwani, Prashant J. [1 ,4 ]
Ahmad, Farhan [1 ]
机构：
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India
[2] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran
[3] Delhi Pharmaceut Sci & Res Univ DPSRU, Dept Pharmaceut, New Delhi, India
[4] Saveetha Inst Med & Tech Sci, Saveetha Dent Coll, Ctr Transdisciplinary Res, Dept Pharmacol, Chennai, India
来源：
MEDICAL ONCOLOGY | 2023年 / 40卷 / 06期
关键词：
Cancer; Dasatinib; Tyrosine kinase inhibitor; Solubility; Bioavailability; Side effects; Formulations; CHRONIC MYELOID-LEUKEMIA; NANOSTRUCTURED LIPID CARRIERS; DRUG-INTERACTIONS; CHRONIC PHASE; GROWTH; SRC; PHARMACOKINETICS; COMBINATION; RESISTANCE; BMS-354825;
D O I：
10.1007/s12032-023-02018-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat numerous forms of leukemic and cancer patients and it is 300 times more potent than imatinib. Cancer is the major cause of death globally and need to enumerate novel strategies to coping with it. Various novel therapeutics introduced into the market for ease in treating various forms of cancer. We reviewed and evaluated all the related aspects of dasatinib, which can enhance the knowledge about dasatinib therapeutics methodology, pharmacodynamic and pharmacokinetics, side effects, advantages, disadvantages, various kinds of interactions and its novel formulations as well.
引用
收藏
页数：23
相关论文
共 118 条
  • [1] Alharbi Bader, 2018, Case Rep Dermatol Med, V2018, P4062431, DOI 10.1155/2018/4062431
  • [2] Docetaxel-dasatinib combination: A strategy to overcome unfavorable treatment outcomes due to dose reduction
    Allotey-Babington, Grace Lovia
    Nettey, Henry
    D'Souza, Martin J.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 61
  • [3] Arafath AAMY., 2021, CURRENT ASPECTS PHAR, P161, DOI [10.9734/bpi/caprd/v2/4309f, DOI 10.9734/BPI/CAPRD/V2/4309F]
  • [4] Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
    Araujo, John
    Logothetis, Christopher
    [J]. CANCER TREATMENT REVIEWS, 2010, 36 (06) : 492 - 500
  • [5] Dendrimers as prospective nanocarrier for targeted delivery against lung cancer
    Arora, Virali
    Abourehab, Mohammed A. S.
    Modi, Gyan
    Kesharwani, Prashant
    [J]. EUROPEAN POLYMER JOURNAL, 2022, 180
  • [6] Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
    Bahman, Fatemah
    Pittala, Valeria
    Haider, Mohamed
    Greish, Khaled
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (06):
  • [7] Experience with dasatinib and nilotinib use in pregnancy
    Barkoulas, Theodora
    Hall, Philip D.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (02) : 121 - 128
  • [8] Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
    Beck, Olaf
    Paret, Claudia
    Russo, Alexandra
    Burhenne, Juergen
    Fresnais, Margaux
    Steimel, Kevin
    Seidmann, Larissa
    Wagner, Daniel-Christoph
    Vewinger, Nadine
    Lehmann, Nadine
    Sprang, Maximilian
    Backes, Nora
    Roth, Lea
    Neu, Marie Astrid
    Wingerter, Arthur
    Henninger, Nicole
    El Malki, Khalifa
    Otto, Henrike
    Alt, Francesca
    Desuki, Alexander
    Kindler, Thomas
    Faber, Joerg
    [J]. CANCERS, 2020, 12 (04)
  • [9] Bitencourt Roberta, 2011, Rev. Bras. Hematol. Hemoter., V33, P470, DOI 10.5581/1516-8484.20110124
  • [10] Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
    Blake, Stephen J.
    Hughes, Timothy P.
    Lyons, A. Bruce
    [J]. EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : 612 - 621
12345678910